首页> 美国卫生研究院文献>Tropical Medicine and Infectious Disease >Can the High Sensitivity of Xpert MTB/RIF Ultra Be Harnessed to Save Cartridge Costs? Results from a Pooled Sputum Evaluation in Cambodia
【2h】

Can the High Sensitivity of Xpert MTB/RIF Ultra Be Harnessed to Save Cartridge Costs? Results from a Pooled Sputum Evaluation in Cambodia

机译:可以利用Xpert MTB / RIF Ultra的高灵敏度来节省墨盒成本吗?柬埔寨痰液综合评估结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite the World Health Organization recommending the use of rapid molecular tests for diagnosing tuberculosis (TB), uptake has been limited, partially due to high cartridge costs. Other infectious disease programs pool specimens to save on diagnostic test costs. We tested a sputum pooling strategy as part of a TB case finding program using Xpert MTB/RIF Ultra (Ultra). All persons were tested with Ultra individually, and their remaining specimens were also grouped with 3–4 samples for testing in a pooled sample. Individual and pooled testing results were compared to see if people with TB would have been missed when using pooling. We assessed the potential cost and time savings which different pooling strategies could achieve. We tested 584 individual samples and also grouped them in 153 pools for testing separately. Individual testing identified 91 (15.6%) people with positive Ultra results. One hundred percent of individual positive results were also found to be positive by the pooling strategy. Pooling would have saved 27% of cartridge and processing time. Our results are the first to use Ultra in a pooled approach for TB, and demonstrate feasibility in field conditions. Pooling did not miss any TB cases and can save time and money. The impact of pooling is only realized when yield is low.
机译:尽管世界卫生组织建议使用快速分子检测来诊断结核病(TB),但摄取受到限制,部分原因是药盒成本高。其他传染病计划会合并标本以节省诊断测试成本。我们使用Xpert MTB / RIF Ultra(Ultra)测试了痰池化策略,作为结核病病例发现计划的一部分。所有人员均接受了Ultra的单独测试,其余样品也被分类为3–4个样品,用于合并样品中的测试。比较了个人和合并的测试结果,以查看使用合并时是否会错过结核病患者。我们评估了不同的合并策略可以实现的潜在成本和时间节省。我们测试了584个单独的样本,并将它们分为153个样本池进行单独测试。单个测试确定了91位(15.6%)的Ultra结果为阳性。合并策略还发现100%的个人阳性结果为阳性。合并将节省27%的盒带和处理时间。我们的结果是首次在合并方法中将Ultra用于结核病,并证明了在现场条件下的可行性。汇聚不会错过任何结核病病例,可以节省时间和金钱。只有在产量较低时才能实现合并的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号